FDA Panels Schedules Meeting to Discuss Safety of Avandia®
April 23rd, 2013|
April 23, 2013
A discussion has been scheduled by U.S Food and Drug Administration (FDA) officials to discuss findings of a study on the safety of the GlaxoSmithKline drug Avandia®.
The drug is used in the treatment of Type II Diabetes to help the body better control glucose levels. In September 2010, the medication was pulled from the European market because of serious Drug Injury dangers to patients, including cardiovascular risks.
The FDA acknowledged the drug’s risks by limiting its use to certain patients and calling for a new study to reevaluate the effects of the medication. The study was performed at Duke University and conclusive results were recently reached.
According to an article released by Medscape Today, the FDA has scheduled its Endocrinologic and Metabolic Drugs Advisory and Drug Safety and Risk Management Advisory Committees to convene this June to discuss the results. Some experts believe the findings could lead to the drug being completely pulled from the market. Many feel this is the best solution because safer, more effective drugs are currently on the market.
The Birmingham Personal Injury Attorneys with Norris Injury Lawyers applaud the efforts made to ensure that medications available to patients in the United States are safe. The firm is hopeful the upcoming panel meeting will be successful in determining the safety of Avandia® and the best course of action to take in distributing the drug.